“Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active Psoriatic Arthritis: Results from a Phase 2 Trial”, J of Skin, vol. 8, no. 2, p. s383, Mar. 2024, doi: 10.25251/skin.8.supp.383.